CN104688745B - 用于抑制肌萎缩的方法 - Google Patents

用于抑制肌萎缩的方法 Download PDF

Info

Publication number
CN104688745B
CN104688745B CN201510064814.6A CN201510064814A CN104688745B CN 104688745 B CN104688745 B CN 104688745B CN 201510064814 A CN201510064814 A CN 201510064814A CN 104688745 B CN104688745 B CN 104688745B
Authority
CN
China
Prior art keywords
compound
muscle
alkyl
another aspect
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510064814.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104688745A (zh
Inventor
C·M·亚当斯
S·D·康凯尔
M·苏亚
M·威尔士
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation
Original Assignee
University of Iowa Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation filed Critical University of Iowa Research Foundation
Publication of CN104688745A publication Critical patent/CN104688745A/zh
Application granted granted Critical
Publication of CN104688745B publication Critical patent/CN104688745B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/28—Unsaturated compounds polycyclic
    • C07C61/29—Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
CN201510064814.6A 2010-05-20 2011-05-19 用于抑制肌萎缩的方法 Active CN104688745B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34681310P 2010-05-20 2010-05-20
US61/346,813 2010-05-20
US201161445488P 2011-02-22 2011-02-22
US61/445,488 2011-02-22
CN201180035480.XA CN103037692B (zh) 2010-05-20 2011-05-19 用于抑制肌萎缩的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180035480.XA Division CN103037692B (zh) 2010-05-20 2011-05-19 用于抑制肌萎缩的方法

Publications (2)

Publication Number Publication Date
CN104688745A CN104688745A (zh) 2015-06-10
CN104688745B true CN104688745B (zh) 2019-11-12

Family

ID=44992066

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510064814.6A Active CN104688745B (zh) 2010-05-20 2011-05-19 用于抑制肌萎缩的方法
CN201180035480.XA Active CN103037692B (zh) 2010-05-20 2011-05-19 用于抑制肌萎缩的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180035480.XA Active CN103037692B (zh) 2010-05-20 2011-05-19 用于抑制肌萎缩的方法

Country Status (8)

Country Link
US (2) US9856204B2 (enExample)
EP (1) EP2571354B1 (enExample)
JP (2) JP5808797B2 (enExample)
CN (2) CN104688745B (enExample)
AU (2) AU2011255495A1 (enExample)
CA (1) CA2800109C (enExample)
IL (2) IL223153A (enExample)
WO (1) WO2011146768A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571354B1 (en) 2010-05-20 2020-07-08 University of Iowa Research Foundation Ursolic acid for inhibiting muscle atrophy
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2014022772A1 (en) * 2012-08-03 2014-02-06 University Of Iowa Research Foundation Tomatidine, analogs thereof, compositions comprising same, and uses for same
JP5841234B2 (ja) 2011-03-31 2016-01-13 ザ プロクター アンド ギャンブルカンパニー フケ／脂漏性皮膚炎の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法
CN106822153B (zh) * 2011-06-06 2019-12-17 爱荷华大学研究基金会 用于抑制肌萎缩的方法
EP2813237A4 (en) 2012-01-30 2015-08-12 Postech Acad Ind Found PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES WITH TENC1 EXPRESSION OR ACTIVITY SUPPRESSOR
CN102675406A (zh) * 2012-06-04 2012-09-19 福州大学 抗肿瘤活性的熊果酸含氮杂环类结构修饰物及其制备方法
MX2014014898A (es) 2012-06-06 2015-03-04 Procter & Gamble Sistemas y metodos de identificacion de agentes cosmeticos para composiciones para el cuidado del cabello/cuero cabelludo.
WO2014014530A1 (en) * 2012-07-17 2014-01-23 Mylari Banavara L Ursolic acid salts for treating diabetes and obesity
US10036741B2 (en) 2012-08-15 2018-07-31 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating an array of skin disorders
KR101523953B1 (ko) * 2013-05-29 2015-06-01 부산대학교 산학협력단 비파잎 추출물을 유효성분으로 함유하는 근육 감소증 예방 또는 치료용 조성물
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
US20160256511A1 (en) * 2013-11-13 2016-09-08 In Ingredients, Inc. Compositions and methods for the treatment or prophylaxis of circadian protein related conditions
NL2015032B1 (en) * 2015-06-26 2017-01-24 Vitalnext B V Compositions and methods for the treatment of malnutrition.
JP6791977B2 (ja) 2015-10-29 2020-11-25 エミオン インコーポレイテッドＥｍｍｙｏｎ， Ｉｎｃ． 骨格筋の肥大剤としてのフロスタン−３オール誘導体
JPWO2018079715A1 (ja) * 2016-10-27 2019-09-19 サントリーホールディングス株式会社 Ｆｏｘｏ１活性阻害用組成物
EP3681507B8 (en) 2017-09-13 2024-03-13 Emmyon, Inc. Ursolic acid morpholine and diethanolamine salts
US10137138B1 (en) 2018-05-29 2018-11-27 King Saud University Sulfonylurea derivatives of oleanolic acid
KR20200066013A (ko) * 2018-11-30 2020-06-09 씨제이제일제당 (주) 사료 첨가제 조성물 및 이를 포함하는 사료 조성물
US10734096B1 (en) * 2019-11-29 2020-08-04 Kpn Innovations, Llc Methods and systems for optimizing supplement decisions
CN113528675A (zh) * 2021-07-22 2021-10-22 安徽农业大学 一种基于肌抑制素基因mstn鉴定鸭屠宰性状的分子标记及其鉴定方法和应用
KR102748036B1 (ko) * 2021-09-28 2024-12-27 동의대학교 산학협력단 라벤더 추출물을 유효 성분으로 포함하는 근감소증 예방 또는 개선용 조성물
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
WO2026090182A1 (en) 2024-10-23 2026-04-30 Emmyon, Inc. Glp-1 receptor agonist and ursolic acid combinations and use thereof for increasing weight loss while improving muscle mass and strength
CN122163736A (zh) * 2026-05-11 2026-06-09 华润三九（南昌）药业有限公司 强力枇杷露在制备改善和/或治疗肌肉萎缩药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2910470A (en) 1958-11-20 1959-10-27 Searle & Co 3-oxocona-1, 4-dienine and intermediates for its preparation
NL124636C (enExample) 1965-02-26
NL6509936A (enExample) 1965-07-30 1967-01-31
US3625941A (en) 1968-04-30 1971-12-07 Searle & Co ALPHA-(2-LOWER ALKYL-2-{8 2-(6-LKOXY OR TERTIARY AMINO-1,2,3,4-TETRAHYDRONAPHTH-1-YLIDEN) ethyl{9 -3-OXO CYCLO-PERET-1-YLIDENAMINOXY OR OXO HYDROZINO) ALKONIC ACID AND ASYMMETRIC FORCES FOR THEIR PRODUCTION
GB1414047A (en) 1973-03-15 1975-11-12 Biorex Laboratories Ltd Ursolic acid derivatives
AU578068B2 (en) 1984-03-08 1988-10-13 Nippon Zoki Pharmaceutical Co., Ltd. Hydantoin derivatives and pharmaceutical compositions containing them
AT396589B (de) 1990-06-05 1993-10-25 Chemie Linz Gmbh Verfahren zur herstellung von allantoin
US5422350A (en) 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
BE1008235A5 (nl) 1994-03-25 1996-02-20 Univ Gent Analysemethode geschikt om beta-agonisten en beta-antagonisten op te sporen.
CA2193679A1 (en) * 1994-06-24 1996-01-04 Tadaaki Ohgi Triterpene derivative and medicinal composition
JP3041232B2 (ja) * 1995-11-16 2000-05-15 日本ケミカルリサーチ株式会社 癌転移抑制剤
KR20000019716A (ko) 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
EP1321145A4 (en) 2000-07-31 2006-03-22 Nisshin Oillio Ltd ANTITUMOR SUBSTANCES
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
AU2002224130A1 (en) 2000-11-30 2002-06-11 The Nisshin Oillio, Ltd. Foods and beverages for whitening and orally administered whitening agents
JP3716975B2 (ja) 2001-10-30 2005-11-16 独立行政法人科学技術振興機構 新規ナリンゲニン誘導体及びその用途
PT1463497E (pt) 2001-12-06 2011-12-20 Gtx Inc Tratamento do desgaste muscular com moduladores selectivos do receptor de androgénios
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
CN100506092C (zh) 2004-06-08 2009-07-01 千南成 中药解酒饮料
EP1618881A1 (en) 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
US7612045B2 (en) * 2004-09-14 2009-11-03 Sequoia Sciences, Inc. Compounds, compositions and methods for controlling biofilms and bacterial infections
US20060083793A1 (en) 2004-09-29 2006-04-20 Gardiner Paul T Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker
AU2005330504B2 (en) 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
KR101254938B1 (ko) * 2005-06-10 2013-04-16 포라가세이고오교오가부시끼가이샤 신규 트리테르펜산 유도체 및 이를 포함하는 피부 외용제
US20080317885A1 (en) * 2005-07-15 2008-12-25 Baker Donald J Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals
WO2007053915A2 (en) 2005-11-09 2007-05-18 Universiteit Gent Naringenin derivatives with selectivity on ers
CN1771968A (zh) * 2005-11-14 2006-05-17 广东天之骄药物开发有限公司 一种熊果酸脂肪乳注射剂及其制备方法
JPWO2007097289A1 (ja) 2006-02-20 2009-07-16 武田薬品工業株式会社 新規医薬
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008063318A2 (en) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Betulinic acid, derivatives and analogs thereof and uses therefor
US20100305068A1 (en) 2006-11-09 2010-12-02 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
US20090143279A1 (en) * 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
US20100040568A1 (en) 2008-04-30 2010-02-18 Skinmedica, Inc. Steroidal compounds as melanogenesis modifiers and uses thereof
CN101318985A (zh) * 2008-07-23 2008-12-10 谢佳良 一种熊果酸的制备方法及其产品和应用
JP2010095459A (ja) 2008-10-15 2010-04-30 Kinki Univ 脂肪蓄積・代謝改善剤、抗ＴＮＦ−α作用剤、及び新規トリテルペン化合物
US20100104669A1 (en) 2008-10-28 2010-04-29 Scheffler Armin Method for preparing an aqueous solution containing triterpenic acid, aqueous solution containing triterpenic acid, and use thereof
US20100204121A1 (en) * 2009-02-10 2010-08-12 Romero Augustin T Dietary supplements containing terpenoid acids of maslinic acid or oleanolic acid and process for enhancing muscle mass in mammals
EP2246050A1 (en) 2009-04-27 2010-11-03 IMR - International Medical Research - Partner GmbH Combination therapy comprising mechanical vibration for the treatment of a disease of the musculoskeletal or nervous system
US20120135094A1 (en) 2009-05-14 2012-05-31 Rutgers, The State University Of New Jersey Oregano and mint anti-inflammatory compositions and methods
WO2011056549A1 (en) 2009-10-27 2011-05-12 Access Business Group International Llc Molecular targets and dietary modulators of exercise-induced muscle damage
EP2571354B1 (en) 2010-05-20 2020-07-08 University of Iowa Research Foundation Ursolic acid for inhibiting muscle atrophy
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Also Published As

Publication number Publication date
US9856204B2 (en) 2018-01-02
CN103037692B (zh) 2015-02-25
EP2571354B1 (en) 2020-07-08
CA2800109A1 (en) 2011-11-24
JP5808797B2 (ja) 2015-11-10
EP2571354A4 (en) 2014-04-02
JP6152149B2 (ja) 2017-06-21
HK1207299A1 (en) 2016-01-29
AU2011255495A1 (en) 2012-12-06
CA2800109C (en) 2020-06-30
IL250259A0 (en) 2017-03-30
IL250259B (en) 2020-04-30
CN104688745A (zh) 2015-06-10
EP2571354A1 (en) 2013-03-27
AU2017200927A1 (en) 2017-03-02
AU2017200927B2 (en) 2018-09-06
JP2016026175A (ja) 2016-02-12
CN103037692A (zh) 2013-04-10
US20180118657A1 (en) 2018-05-03
IL223153A0 (en) 2013-02-03
JP2013526580A (ja) 2013-06-24
IL223153A (en) 2017-02-28
AU2011255495A2 (en) 2013-10-24
WO2011146768A1 (en) 2011-11-24
US20130203712A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
CN103037692B (zh) 用于抑制肌萎缩的方法
US10576091B2 (en) Tomatidine, analogs thereof, compositions comprising same, and uses for same
EP3520793B1 (en) Substances and compostions for use in methods of inhibiting muscle atrophy
AU2012268036A1 (en) Methods of inhibiting muscle atrophy
EA020496B1 (ru) Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
EP3991795B1 (en) Novel use of nicotinamide mononucleotide (nmn) and nicotinamide riboside (nr)
HK1207299B (en) Methods for inhibiting muscle atrophy
HK1238578A1 (en) Methods of inhibiting muscle atrophy
JP7125792B2 (ja) 神経変性疾患の治療又は予防用Ｎｕｒｒ１／ＲＸＲ活性化剤
HK1238578B (en) Methods of inhibiting muscle atrophy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207299

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant